Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. Saund will discuss the company’s proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators.
To view the full press release, visit https://nnw.fm/O1lLk
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer